Global Health Limited reported a strong finish to the 2025-26 fiscal year, with consolidated revenue reaching ₹44,102.66 million. For the quarter ended March 31, 2026, the company achieved a consolidated profit after tax of ₹1,416.53 million. Demonstrating confidence in its growth trajectory, the Board of Directors has recommended a final dividend of ₹0.50 per share (25%) for the financial year, subject to shareholder approval.
Fiscal Year Financial Highlights
Global Health Limited has delivered robust performance for the financial year ended March 31, 2026. On a consolidated basis, the company recorded total revenue from operations of ₹44,102.66 million, up from ₹36,923.45 million in the previous year. The annual consolidated profit after tax stood at ₹5,540.68 million, reflecting the company’s sustained operational efficiency.
Dividend Proposal
Following the positive financial results, the Board of Directors has recommended a final dividend of ₹0.50 per equity share, having a face value of ₹2/- each. This dividend payout is subject to approval by the company’s shareholders at the upcoming Annual General Meeting. Once approved, the payment will be processed within 30 days of the meeting date.
Strategic Growth and Leadership Changes
The company continues to expand its footprint, having recently finalized a built-to-suit lease arrangement for a 400-bed hospital in Varanasi. Additionally, the company entered into a Business Transfer Agreement for a 79-bed super-speciality hospital in Indore. To bolster its leadership team, Global Health Limited has appointed Mr. Kedar Ashok Apte as Chief Marketing & Growth Officer and Mr. Jagdeep Singh as General Counsel, effective May 14, 2026. These appointments align with the company’s focus on long-term strategy and robust corporate governance.
Source: BSE
